KSP-0914 / Kissei - LARVOL DELTA

An initial report of memory avoidance whole brain radiotherapy to treat brain metastases. (PubMed, Neurooncol Adv) - P2 | "The cognitive decline rates of 17.2% and 48.3% at 3 and 6 months for patients receiving MA-WBRT compare favorably to the 3- and 6-month cognitive decline rates of 50% and 60% seen on NRG CC001. A direct comparison of MA-WBRT plus memantine vs. HA-WBRT plus memantine is forthcoming in a randomized phase 2 trial (NCT07248228)."

Journal • Oncology • Solid Tumor

An all-in-one workflow for emergency hippocampal-avoidance whole-brain radiotherapy in brain metastases, with optional online adaptive extension. (PubMed, J Appl Clin Med Phys) - "The AIO workflow for managing emergency patients with BMs is feasible and safe, facilitating prompt initiation of highly efficient radiotherapy during the first treatment session, eliminating delays. Subsequent online ART effectively corrects rotational deviations, ensuring adequate prescription dose coverage of target volumes while optimizing dose distribution to normal tissues. HA-WBRT incorporating the AIO workflow with online adaptation demonstrates potential for timely control and alleviation of acute symptoms."

Journal • Oncology • Pain • Solid Tumor

Hippocampal-Avoidance Whole-Brain Radiotherapy: Dosimetric Comparison of 3D-CRT, IMRT, and VMAT for Brain Metastases from Lung Cancer. (PubMed, Cancers (Basel)) - "HA-WBRT with IMRT and VMAT significantly reduced the hippocampal dose while maintaining optimal PTV coverage. VMAT is preferred for its balance of efficacy, protection, and treatment time, while IMRT represents a feasible approach for facilities without VMAT, though it requires stricter dose control and longer treatment times."

Journal • Lung Cancer • Oncology • Solid Tumor